Amol J Ghia1,2, Jonathan D Tward1, Christopher J Anker1, Kenneth M Boucher3, Randy L Jensen4, Dennis C Shrieve1. 1. Department of Radiation Oncology, 1950 Circle of Hope, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112. 2. Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX. 3. Department of Oncological Sciences, 1950 Circle of Hope, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112. 4. Department of Neurosurgery, 1950 Circle of Hope, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112.
Abstract
OBJECTIVE: To investigate the influence of stereotactic radiosurgery on the risk of hemorrhage from brain metastases from malignant melanoma. METHODS: A cohort of 110 patients treated with stereotactic radiosurgery (SRS) for 358 melanoma brain metastases was identified. The incidence of hemorrhage before and after SRS was determined by review of serial MRI scans. Statistical analysis was performed to determine the influence of SRS on rate of hemorrhage. Overall survival (OS) and local control (LC) were assessed and prognostic factors, including hemorrhage pre- or post-SRS were analyzed. RESULTS: At presentation 83 of 358 (23.2%) melanoma metastases had hemorrhaged in 44 patients. Following SRS, 73 hemorrhages occurred in 358 treated tumors (20.4%). These rates were not significantly different; p=0.362, HR=0.846 (95% CI 0.591-1.211). The risk of post-SRS hemorrhage in patients was statistically significantly linked to previous hemorrhage. Fourteen of 65 patients (21.5%) who presented without hemorrhage prior to SRS subsequently demonstrated hemorrhage. Twenty-four of 44 patients (54.5%) who presented with hemorrhage went on to demonstrate further hemorrhage following SRS; p=0.005, HR 2.47 (95% CI 1.24-11.3). Mixed effects logistic regression modeling showed no influence of SRS on the risk of hemorrhage of a given lesion (p=0.99).OS at 1 year was better for patients presenting with a single metastasis (41.2%) compared to multiple metastases (20.3%, p=0.009). LC was 60.4% at 1 year following SRS. LC was significantly lower for metastases demonstrating hemorrhage either pre-SRS (51.7% vs 64.9%, p=0.03) or post-SRS (32.7% vs. 67.8%, p<0.001). CONCLUSIONS: The current data show that SRS does not alter the risk of subsequent hemorrhage of treated metastases. However, hemorrhage may complicate follow-up assessment of response and LC following SRS. Careful assessment of imaging following SRS should include awareness that hemorrhage may mimic treatment failure in these patients.
OBJECTIVE: To investigate the influence of stereotactic radiosurgery on the risk of hemorrhage from brain metastases from malignant melanoma. METHODS: A cohort of 110 patients treated with stereotactic radiosurgery (SRS) for 358 melanoma brain metastases was identified. The incidence of hemorrhage before and after SRS was determined by review of serial MRI scans. Statistical analysis was performed to determine the influence of SRS on rate of hemorrhage. Overall survival (OS) and local control (LC) were assessed and prognostic factors, including hemorrhage pre- or post-SRS were analyzed. RESULTS: At presentation 83 of 358 (23.2%) melanoma metastases had hemorrhaged in 44 patients. Following SRS, 73 hemorrhages occurred in 358 treated tumors (20.4%). These rates were not significantly different; p=0.362, HR=0.846 (95% CI 0.591-1.211). The risk of post-SRS hemorrhage in patients was statistically significantly linked to previous hemorrhage. Fourteen of 65 patients (21.5%) who presented without hemorrhage prior to SRS subsequently demonstrated hemorrhage. Twenty-four of 44 patients (54.5%) who presented with hemorrhage went on to demonstrate further hemorrhage following SRS; p=0.005, HR 2.47 (95% CI 1.24-11.3). Mixed effects logistic regression modeling showed no influence of SRS on the risk of hemorrhage of a given lesion (p=0.99).OS at 1 year was better for patients presenting with a single metastasis (41.2%) compared to multiple metastases (20.3%, p=0.009). LC was 60.4% at 1 year following SRS. LC was significantly lower for metastases demonstrating hemorrhage either pre-SRS (51.7% vs 64.9%, p=0.03) or post-SRS (32.7% vs. 67.8%, p<0.001). CONCLUSIONS: The current data show that SRS does not alter the risk of subsequent hemorrhage of treated metastases. However, hemorrhage may complicate follow-up assessment of response and LC following SRS. Careful assessment of imaging following SRS should include awareness that hemorrhage may mimic treatment failure in these patients.
Authors: S D Lavine; Z Petrovich; A A Cohen-Gadol; L S Masri; D L Morton; S J O'Day; R Essner; V Zelman; C Yu; G Luxton; M L Apuzzo Journal: Neurosurgery Date: 1999-01 Impact factor: 4.654
Authors: Donald N Liew; Hideyuki Kano; Douglas Kondziolka; David Mathieu; Ajay Niranjan; John C Flickinger; John M Kirkwood; Ahmad Tarhini; Stergios Moschos; L Dade Lunsford Journal: J Neurosurg Date: 2010-06-04 Impact factor: 5.115
Authors: E Shaw; C Scott; L Souhami; R Dinapoli; R Kline; J Loeffler; N Farnan Journal: Int J Radiat Oncol Biol Phys Date: 2000-05-01 Impact factor: 7.038
Authors: Ugur Selek; Eric L Chang; Samuel J Hassenbusch; Almon S Shiu; Frederick F Lang; Pamela Allen; Jeffrey Weinberg; Raymond Sawaya; Moshe H Maor Journal: Int J Radiat Oncol Biol Phys Date: 2004-07-15 Impact factor: 7.038
Authors: David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran Journal: Lancet Date: 2004-05-22 Impact factor: 79.321
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Maximilian Rauch; Daniel Tausch; Susanne Stera; Oliver Blanck; Robert Wolff; Markus Meissner; Hans Urban; Elke Hattingen Journal: J Neurooncol Date: 2021-03-24 Impact factor: 4.130
Authors: Felix Ehret; David Kaul; Lucas Mose; Volker Budach; Peter Vajkoczy; Christoph Fürweger; Alfred Haidenberger; Alexander Muacevic; Felix Mehrhof; Markus Kufeld Journal: Cancers (Basel) Date: 2022-01-18 Impact factor: 6.639